Business
Kura Oncology Reports Strong Clinical Activity and Safety with Darlifarnib + Adagrasib in KRAS G12C-Mutated Solid Tumors
– Tumor shrinkage observed in 77% of response-evaluable patients, including in heavily pretreated and KRASi-experienced patients – – ORRs were 67% in PDAC, 50% in NSCLC, and 29% in KRASi-naïve CRC patients – – Results reinforce darlifarnib’s potential as a precision combination agent across targeted therapies – – Clear clinical activity in KRASi-experienced patients and manageable safety profile – – Virtual investor event on June 3, 2026, at 12:15 p.m. PT / 3:15 p.m. ET – SAN DIEGO, May 26, 2026
About this update from Kura Oncology, Inc.
– Tumor shrinkage observed in 77% of response-evaluable patients, including in heavily pretreated and KRASi-experienced patients – – ORRs were 67% in PDAC, 50% in NSCLC, and 29% in KRASi-naïve CRC patients – – Results reinforce darlifarnib’s potential as a precision combination agent across targeted therapies – – Clear clinical activity in KRASi-experienced patients and manageable safety profile – – Virtual investor event on June 3, 2026, at 12:15 p.m. PT / 3:15 p.m. ET – SAN DIEGO, May 26, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company focused on precision medicines for the treatment of cancer, today reported compelling first-in-human data from the FIT-001 clinical trial of its next-generation farnesyl transferase inhibitor (FTI) darlifarnib in combination with adagrasib in heavily pretreated patients with KRAS G12C-mutated advanced solid tumors. The results will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting on May 30, 2026. The combination of darlifarnib plus adagrasib demonstrated meaningful antitumor activity in heavily pretreated pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC) patients with prior KRAS inhibitor (KRASi) exposure, as well as KRASi-naïve colorectal cancer (CRC) patients. These data provide clinical proof-of-mechanism for Kura’s FTI platform as a precision combination that blocks RHEB-dependent mTORC1 signaling, a key resistance pathway shared across multiple targeted therapy classes. “These results are very encouraging for patients and represent a major milestone for the FTI field,” said Troy Wilson, Ph.D., J.D., President and Chief Executive Officer of Kura Oncology. “Darlifarnib delivered robust tumor shrinkage and high objective response rates across KRAS G12C-mutated PDAC, NSCLC and CRC. These data compare favorably to adagrasib monotherapy benchmarks and demonstrate consistent, meaningful clinical activity in three difficult-to-treat tumor types. This marks “three-for-three” for targeting the mTORC1-RHEB pathway using an FTI approach to overcome resistance to targeted therapies, building on prior positive combinations with VEGFR tyrosine kinase inhibitors and PI3Kα inhibitors, and now KRAS inhibitors. With compelling clinical activity across multiple tumor types and a manageable safety p...
View stock analysis, news, and events for Kura Oncology, Inc.